"CHEBI:64357"^^ . "42613"^^ . "FDA"^^ . "IDEC-102CNNCI" . . _:b785609 _:b785610 . "C2B8 Monoclonal AntibodySYNCI" . _:b709410 . "Amino Acid, Peptide, or Protein"^^ . "RituxanBRNCI" . _:b785608 _:b785609 . _:b638133 . "IDEC-C2B8CNNCI" . "Monoclonal Antibody IDEC-C2B8SYNCI" . _:b785607 _:b785608 . _:b709408 . "687451"^^ . _:b785611 _:b709410 . _:b709408 . _:b785611 . "42613"^^ . "174722-31-7"^^ . . "4F4X42SYQ6"^^ . _:b709409 . _:b709410 . "Immunologic Factor"^^ . _:b785610 _:b709409 . . _:b785609 _:b709408 . _:b785607 _:b709406 . "RituximabPTNCI" . "A drug used to treat certain types of B-cell non-Hodgkin lymphoma. It is also used with other drugs to treat chronic lymphocytic leukemia and rheumatoid arthritis. It is being studied in the treatment of other types of cancer and other conditions. Rituximab binds to a protein called CD20, which is found on B-cells, and may kill cancer cells. It is a type of monoclonal antibody.NCI-GLOSS" . . "RituxanPTNCI-GLOSSCDR0000505945" . "Rituximab"^^ . "A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)NCI" . "RITUXIMABPTFDA4F4X42SYQ6" . _:b638133 _:b733657 . _:b709406 . _:b733657 _:b785607 . "Rituximab"^^ . _:b709407 . _:b709406 . _:b709408 . "RituximabSYNCITCGA" . _:b709409 . _:b709407 . _:b709407 . "Chimeric Anti-CD20 AntibodySYNCI" . . "MabTheraFBNCI" . _:b638133 . "rituximabPTNCI-GLOSSCDR0000045525" . _:b709409 . "C0732355"^^ . "Non-Hodgkins lymphoma; indolent follicular lymphoma; chronic lymphocytic leukemia, or other B-cell tumors; progressive large cell lymphoma; acute lymphoblastic leukemia; central nervous system lymphoma"^^ . _:b785608 _:b709407 . _:b709406 . "IDEC-C2B8 Monoclonal AntibodySYNCI" . _:b709410 . "C1702"^^ . "Rituximab"^^ . "Diffuse Large B-cell, CD20-positive, Non-Hodgkins Lymphoma"^^ . _:b785610 _:b785611 . _:b733657 .